Detection of CK19, CK20 and EGFR mRNAs in peripheral blood of carcinoma patients: correlation with clinical stage of disease

Gradilone, Angela; Gazzaniga, Paola; Silvestri, Ida; Gandini, Orietta; Trasatti, L.; Lauro, Salvatore; Frati, Luigi; Aglianò, Anna Maria

doi:10.3892/or.10.1.217

Cited by 35 publications

(43 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In recent years, there have been many reports on the RT-PCR detection of CTCs in the peripheral blood, bone marrow, and/or peritoneal lavage of patients with gastrointestinal cancer (Pantel et al, 1999;Yamaguchi et al, 2000;Stathopoulou et al, 2002;Gradilone et al, 2003;Dandachi et al, 2005;Uen et al, 2006). Compared with bone marrow and lymph nodes, blood collection is a minimally invasive procedure and blood can be sampled throughout the course of the disease (Böckmann et al, 2001;Huang et al, 2003;Pantel and Alix-Panabières, 2010;Bednarz-Knoll et al, 2011).…”

Section: Discussionmentioning

confidence: 99%

“…In previous studies, many target genes have been used to detect CTCs in gastrointestinal carcinoma, such as CEA, MUC1, hTERT, cMet, CK18, CK19, and CK20 (Soeth et al, 1997;Yamaguchi et al, 2000;Katsumata et al, 2006;Uen et al, 2006;Wu et al, 2006;Xi et al, 2007;Tsouma et al, 2008;Lagoudianakis et al, 2009). Cytokeratins are frequently used to detect the CTCs in peripheral blood (Weitz et al, 1999;Gradilone et al, 2003;Wang et al, 2006;Wang et al, 2007). The mRNAs of CK19 and CK20 have been successfully used to detect CTCs in the peripheral blood of patients with breast cancer, lung cancer, and gastrointestinal carcinoma (Mori et al, 1996;Denis et al, 1997;Peck et al, 1998).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of MUC1, CK20, and hTERT expression in peripheral blood of gastrointestinal cancer patients in search of diagnostic criteria

Küçükyıldırım¹,

Erdem²,

Saglar³

et al. 2014

Turk J Biol

View full text Add to dashboard Cite

The goal of this study was to identify the optimal marker or marker combinations for detection of gastrointestinal malignancies using reverse-transcriptase polymerase chain (RT-PCR) reaction. To detect the presence of tumors, we analyzed mucin 1 (MUC1), cytokeratin 19 (CK19), cytokeratin 20 (CK20), and human telomerase reverse transcriptase (hTERT) mRNA in the peripheral blood of 31 patients with gastrointestinal (esophagus, stomach, and colorectal) cancer and 30 healthy individuals. In RT-PCR analysis of the peripheral blood, 77.4% (24/31), 61.29% (19/31), and 45.16% (14/31) of cancer patients were positive for MUC1, CK20, and hTERT mRNA, respectively. According to our results, any one of these mRNA markers is a predictor of the presence of gastrointestinal tumors (P < 0.001) and colorectal tumors (P < 0.05). However, they did not have predictive potential for presence of metastasis in gastrointestinal tumors. As a result, combination of these 3 tumor-specific mRNA markers would increase the detection rate and may be clinically helpful in predicting tumor presence.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Evaluation of MUC1, CK20, and hTERT expression in peripheral blood of gastrointestinal cancer patients in search of diagnostic criteria

Küçükyıldırım¹,

Erdem²,

Saglar³

et al. 2014

Turk J Biol

View full text Add to dashboard Cite

show abstract

“…The intermediate filament CK19 has emerged as the PCR-marker of choice for microdisseminated breast cancer cells [8,[31][32][33][34][35]. CK19 is stably expressed in epithelial tissues and tumors but not usually in mesenchymal and/or haematopoietic cells [11,12]. Alternative markers tested by different groups have been Muc-1, urokinase type plasminogen activator receptor (uPAR), EpCAM and mammaglobin each originally considered breast cancer specific [36][37][38].…”

Section: Discussionmentioning

confidence: 99%

“…After the addition of the RNAstabilizer, samples were stored at minus 20°C until further analysis, allowing sample batching, which is important for routine clinical use. The intermediate filament CK19 has emerged as the PCR-marker of choice for microdisseminated breast cancer cells [8,[31][32][33][34][35]. CK19 is stably expressed in epithelial tissues and tumors but not usually in mesenchymal and/or haematopoietic cells [11,12].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of a RT-PCR based routine screening tool for the detection of disseminated epithelial cells in the bone marrow of breast cancer patients

Becker

Becker-Pergola

Banys

et al. 2008

Breast Cancer Res Treat

View full text Add to dashboard Cite

International audienceNumerous studies have shown that the presence of clinically occult disseminated tumor cells (DTC's) in the bone marrow (BM) of breast cancer patients is associated with an unfavourable clinical outcome. Immunocytochemistry (ICC) remains the gold standard for their detection. While assays based on RT-PCR are available, they have not been used for routine detection of DTC's. To assess the quality of the assay, we performed a direct comparison of DTC detection rates in a large cohort of 385 patients using both standardized ICC and real-time RT-PCR protocols. Correlation rates were assessed, and results were compared with clinical data. A significant correlation between ICC and RT-PCR was observed ( < 0.01). Positivity rates were similar (both 35%) and the results of both methods agreed in 73% of cases (280/385). We describe a real-time RT-PCR based protocol for DTC-detection that has been specifically designed for routine clinical laboratory use. As such, RT-PCR has the potential to become an alternative testing method for BM evaluation in breast cancer patients

show abstract

Application of immunomagnetic cell enrichment in combination with RT‐PCR for the detection of rare circulating head and neck tumor cells in human peripheral blood

Tong

Yang

Lang

et al. 2007

Cytometry Part B Clinical

View full text Add to dashboard Cite

Detection of rare, circulating tumor cells (CTC's) in human peripheral blood is a potential indicator of prognosis and diagnosis in oncology. Typical methods to detect these CTC's are either by immunocytochemistry (ICCS) or RT-PCR. However without accurate, rapid, and reproducible enrichment processes, these detection techniques are labor intensive and/or unreliable. In this article, a repeatable enrichment process that included a flow-through immunomagnetic cell separation system, the quadrupole magnetic sorter (QMS) was optimized with the aid of a statistical analysis software package. The QMS was operated in a negative mode of operation by immunomagnetically targeting normal human peripheral blood lymphocytes (PBL) through the CD45 surface marker. Three head and neck squamous carcinoma cell lines (HNSCC), Detroit-562, SCC-4, and CAL-27, were used to determine the sensitivity of RT-PCR for the epidermal growth factor receptor (EGFR) in spiked PBL. The detection purity needed for detection was found to be one cell in 10 4 , one cell in 10 3 , and one cell in 10 5 for the Detroit-562, SCC-4, and CAL-27, respectively. The actual number of cancer cells needed for RT-PCR detection ranged from 30 to 1 cell. To mimic the potential concentration of rare CTC present in peripheral blood of cancer patients, the spiking concentration was chosen to be one cancer cell per 10 5 total leukocytes from healthy donors. Using a single step immunomagnetic labeling, the final, optimized enrichment process produced a 57.6 6 30.3-fold (n 5 6) enrichment of the rare cancer cells with a final cancer cell recovery of (77.8 6 6.6)%. q 2007 Clinical Cytometry Society Key terms: immunomagnetic cell separation; circulating tumor cells; reverse transcriptase polymerase chain reaction; head and neck squamous carcinoma cell; Detroit-562; epidermal growth factor receptor; immunocytochemistry staining; quadrupole magnetic sorter Head and Neck cancer comprises *6% of all cancers which results, globally, in *550,000 cases a year. According to the statistics of American Cancer Society, 39,250 new cases of cancer of the oral cavity, oropharynx, pharynx, and larynx are estimated to occur in the US in 2005, and 10,090 deaths were estimated to occur. Greater than 90% of these cases of head and neck cancer are classified as squamous cell carcinomas. For all stages combined, the 5-year survival rate is approximately 58.7%, and this rate has increased slowly in the last 20 years. About 40-50% of the patients will later develop locoregional recurrences, and approximately 80% of these recurrences occur within the first 2 years.Both recent and historical studies have shown that tumor cells are likely to exist in the bone marrow or in the peripheral blood of various types of cancer patients (1-6). It has been presumed that those tumor cells shed from the original tumors and are considered to contribute to the

show abstract

Detection of CK19, CK20 and EGFR mRNAs in peripheral blood of carcinoma patients: correlation with clinical stage of disease

Cited by 35 publications

References 0 publications

Evaluation of MUC1, CK20, and hTERT expression in peripheral blood of gastrointestinal cancer patients in search of diagnostic criteria

Evaluation of MUC1, CK20, and hTERT expression in peripheral blood of gastrointestinal cancer patients in search of diagnostic criteria

Evaluation of a RT-PCR based routine screening tool for the detection of disseminated epithelial cells in the bone marrow of breast cancer patients

Application of immunomagnetic cell enrichment in combination with RT‐PCR for the detection of rare circulating head and neck tumor cells in human peripheral blood

Contact Info

Product

Resources

About